Frontiers in Clinical Drug Research – HIV is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of acquired immune deficiency syndrome (AIDS) and other disorders associated with human immunodeficiency virus (HIV) infection. The scope of the book series covers a range of topics including the medicinal chemistry and pharmacology of natural and synthetic drugs employed in the treatment of AIDS (including HAART) and resulting complications, and the virology and immunological study of HIV and related viruses. Frontiers in Clinical Drug Research – HIV is a valuable resource for pharmaceutical scientists, clinicians and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in HIV/AIDS research. The fifth volume of this series features 5 chapters that cover these topics: - Clinical Eradication of Latent HIV Reservoirs: Where Are We Now? - HIV-1 Genotypic Drug Resistance Testing and Next-Generation Sequencing - Current and Promising Multiclass Drug Regimens and Long-Acting Formulation Drugs in HIV Therapy - Role of Nanotechnology in HIV Diagnosis and Prognosis - Preventive and Therapeutic Features of Combination Therapy for HIV.

Emerging Nanomaterials and Nano-based Drug Delivery Approaches to Combat Antimicrobial Resistance focuses on recent and emerging trends surrounding nanomaterials and nano-drug delivery approaches to combat antimicrobial resistance. The relationship between nanomaterials and antimicrobial activity needs to be deeply explored to meet the challenges of combating antimicrobial resistance. The content of this book is divided into three main topic areas, including (i) how to overcome the existing traditional approaches to combat antimicrobial resistance, (ii) applying multiple drug delivery mechanisms to target multi-drug resistant microbes, and (iii) how nanomaterials can be used as drug carriers. This is an important reference source for those looking to understand how nanotechnology plays an important role in combatting disease and infection. As antimicrobial resistance threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses, and fungi, this is a timely resource. - Outlines how to overcome existing traditional approaches to combatting antimicrobial resistance - Explains how to apply multiple drug delivery mechanisms (MDR) to the target area in order to better combat antimicrobial resistance - Shows how nanomaterials are used as drug carriers in this context

HIV/AIDS continues to be one of the most challenging individual and public health concerns of the present day. According to the UNAIDS, nearly 38 million individuals were living with the infection by the end of 2018, while 1.7 million new cases occurred during that same year. In spite of the numerous advances in the development and delivery of antiretroviral agents, both for treatment and prevention, several challenges remain. This book includes original research and review articles on innovative strategies and approaches for the formulation and delivery of anti-HIV drugs, including genetic material and other biopharmaceuticals. Different local and systemic delivery strategies are addressed based on different technologies intended for oral, transdermal, subcutaneous, vaginal, or rectal administration. Authored by eminent scientists in academia and nonprofit organizations involved in the development of antiretroviral drug products, this collection provides useful information for all those involved in HIV/AIDS treatment and prevention.

During the past two decades, the world scientific community has witnessed major achievements in our understanding of the pathogenesis of HIV infection of the nervous system and HIV-Associated Dementia (HAD). Despite these giant gains, nervous system involvement during AIDS remains a relentlessly progressive disease with a deadly fate in many cases. This book on NeuroAIDS provides a unique resource for both general neurologists as well as basic neuroscientists with profound interests for research on NeuroAIDS. This book has special emphasis on the mechanisms of disease development and progression of HIV-infected patients with NeuroAIDS. The contributors have provided the readers with comprehensive reviews on clinical manifestations of HAD, mechanisms of HIV entry into the central nervous system, the role of cytokines and chemokines in pathogenesis of NeuroAIDS, drug abuse and NeuroAIDS, virus load in HAD, allostasis in HIV and AIDS, stroke in AIDS patients, and neuroimaging of HIV infection of the central nervous system. In addition, there are chapters on Varicella Zoster virus infection of HIV-seropositive and AIDS patients, as well as the molecular basis for opioids and AIDS virus interactions.

Nanotechnology in Diagnosis, Treatment and Prophylaxis of Infectious Diseases delivers comprehensive coverage of the application of nanotechnology to pressing problems in infectious disease. This text equips readers with cutting-edge knowledge of promising developments and future prospects in nanotechnology, paying special attention to microbes that are now resistant to conventional antibiotics, a concerning problem in modern medicine. Readers will find a thorough discussion of this new approach to infectious disease treatment, including the reasons nanotechnology presents a promising avenue for the diagnosis, treatment, and prophylaxis of infectious diseases. - Provides a comprehensive overview of the use of nanotechnology in the treatment and diagnosis of infectious diseases - Covers all common types of infective agents, including bacteria, viruses, fungi, and protozoa, along with their vectors, ticks, mosquitoes, flies, etc. - Delivers commentary from an international researcher base, providing insights across differing economic statuses - Includes a foundation of basic nanotechnological concepts to aid in designing new strategies to combat several pathogenic diseases and cancer - Illustrates the high antimicrobial potential of nanoparticles, ultimately demonstrating how they are a promising alternative class that can be successfully used in fighting a myriad of infections

Antimicrobial agents are essential for the treatment of life-threatening infections and for managing the burden of minor infections in the community. In addition, they play a key role in organ and bone marrow transplantation, cancer chemotherapy, artificial joint and heart valve surgery. Unlike other classes of medicines, they are vulnerable to resistance from mutations in target microorganisms, and their adverse effects may extend to other patients (increased risk of cross-infection). As a consequence, there is a constant requirement for new agents, as well as practices that ensure the continued effective prescribing of licensed agents. Public awareness and concerns about drug resistant organisms has led to widespread publicity and political action in the UK, Europe and worldwide. The control of drug resistance and the implementation of good prescribing practice are now legal requirements in the UK as a result of the UK Health Act (2008). These fundamental changes underscore the need for a thorough understanding of the advantages and risks associated with specific antibiotic choices. This sixth edition of Antimicrobial Chemotherapy continues to be a valuable resource for undergraduates and graduates requiring a thorough grounding in the scientific basis and clinical application of these drugs. This new edition is updated to include the most recently licensed agents, notably in the treatment of viral infections including HIV/AIDS, and contains new guidance on prescribing practice and infection control practices that limit the development and spread of resistant organisms.